Buscar

17/10/2024 P25.03.B RWD OF IDH MUTANT GLIOMAS IN SPAIN, A RETSINE - GEINO STUDY
Mazariegos, M, Girones, R, Del Barco, S, Garcia, A, Velilla, G, Hernandez, A, Alonso, M, Ferreira, L, Luque, N, Fernández,, Quintanar, T, Peralta, S, Ceballos,, Iza, E, Sanchez, M, Martín, EP, Casado, EA, Mazarico, J, Duran, G, Alvarez, P, Ayala, P, Gallego, O, Sarabia, R, de las Penas, R, Nuñez,, Morilla,, Cunquero, A, Cheverria, N, Moya,, Vaz, M, Luque, R, Esteve, A, Pineda, E. P25.03.B RWD OF IDH MUTANT GLIOMAS IN SPAIN, A RETSINE - GEINO STUDY. NEURO-ONCOLOGY. 2024; 26DOI:10.1093/neuonc/noae144.446. PMID:. IF:13.400(Q1/1D).
06/10/2024 Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study
Vidal, N, Climent, MA, Pérez, S, Méndez-Vidal, MJ, Anguera, G, Salas, IM, Gallardo, E, Cuéllar-Rivas, MA, Molina-Cerrillo, J, Martín, A, Rodriguez-Vida, A, Casado, EA, Gonzalez, M, Domènech, M, Kareaga, MM, Calvo, OF, Guzmán, JCV, Estévez, SV, Gonzàlez-del-Alba, A, Puente, J. Impact of COVID-19 infection on genitourinary cancer management. SOGUG-COVID-19: A spanish, multicenter, observational study. Clinical & Translational Oncology. 2024; DOI:10.1007/s12094-024-03744-6. PMID:39369361. IF:2.500(Q3/6D).
01/10/2024 Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study
Bellmunt, J, Maroto, P, Bonfill, T, Vazquez, F, Perez-Gracia, JL, Juanpere, N, Hernandez-Prat, A, Hernandez-Llodra, S, Rovira, A, Juan, OS, Rodriguez-Vida, A. Dual mTOR1/2 Inhibitor Sapanisertib (FTH-003/TAK-228) in Combination With Weekly Paclitaxel in Patients With Previously Treated Metastatic Urothelial Carcinoma: A Phase II Open-Label Study. Clinical Genitourinary Cancer. 2024; 22(5)DOI:10.1016/j.clgc.2024.102123. PMID:38905731. IF:2.700(Q2/3D).
01/10/2024 The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review
Abu Remilah, A, Krayim, B, Amir, E, Tibau, A, Robson, ME, Abuhadra, N, Chen, Y, Shepshelovich, D, Goldvaser, H. The impact of previous therapy on overall-survival in registration clinical trials for 1st line metastatic breast cancer a systemic review. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2024; 202DOI:10.1016/j.critrevonc.2024.104455. PMID:39067779. IF:5.600(Q1/2D).